Dopamine agonist-induced inhibition of neurotransmitter release from the awake squirrel monkey putamen as measured by microdialysis

Journal of Neurochemistry

Volumn 68, Issue 2, 1997, Pages 659-666

  Davis, M Duff ^a   Heffner, Thomas G ^a   Cooke, Leonard W ^a  

^a PFIZER INC   (United States)

Author keywords

Bopamine release; Microdialysis; Monkey; PD 135222; Quinpirole; Talipexole

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; PD 135222; QUINPIROLE; TALIPEXOLE; TETRODOTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; MALE; MICRODIALYSIS; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; PUTAMEN; SQUIRREL MONKEY; WAKEFULNESS;

EID: 0031021492     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.68020659.x     Document Type: Article

References (69)

1. Abraini J. H., Fechtali T., and Rostain J. C. (1994) Lasting effects of dopamine receptor agonists upon striatal dopamine release in free-moving rats: an in vivo voltammetric study. Brain Res. 642, 199-205.
2. Anden N. E. and Grabowska-Anden M. (1990) B-HT 920 is a full agonist at both pre-and postsynaptic D2 dopamine receptors. J. Neural Transm. 79, 209-214.
3. Aosaki T., Kimura M., and Graybiel A. M. (1995) Temporal and spatial characteristics of tonically active neurons of the primate's striatum. J. Neurophysiol. 73, 1234-1241.
4. Ball L. M., Cooke L. W., Corbin A. E., Pugsley T. A., Ninteman F. W., Meltzer L. T., Heffner T. G., and Davis M. D. (1991) Effects of the novel dopamine autoreceptor agonist PD 135222 in neurophysiological, neurochemical and behavioral tests in rodent and monkey. Soc. Neurosci. Abstr. 17, 689.
5. Benkert O., Grunder G., and Wetzel H. (1992) Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Pharmacopsychiatry 25, 254-260.
6. Bergman J., Madras B. K., and Spealman R. D. (1991) Behavioral effects of D1 and D2 receptor antagonists in squirrel monkeys. J. Pharmacol Exp. Ther. 258, 910-917.
7. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. J. Neuro. Sci. 20, 415-455.
8. 3H] dopamine from synaptosomes. J. Pharmacol. Exp. Ther. 248, 514-520.
9. 1 receptor agonists and antagonists. J. Neurochem. 48, 824-831.
10. Camp D. M. and Robinson T. E. (1992) On the use of multiple probe insertions at the same site of repeated intracerebral microdialysis experiments in the nigrostriatal dopamine system of rats. J. Neurochem. 58, 1706-1715.
11. Carlsson A. (1975) Receptor-mediated control of dopamine metabolism, in Pre-and Postsynaptic Receptors (Usdin E. and Bunney W. E., eds). pp. 49-65. Marcel Dekker, New York.
12. 1 adenosine, receptor-mediated inhibition of striatal dopamine release. J. Neurochem. 57, 147-152.
13. Choi W. S., Machida C. A., and Ronnekleiv O. K. (1995) Distribution of dopamine D1, D2, and D5 receptor mRNAs in the monkey brain: ribonuclease protection assay analysis. Mol. Brain Res. 31, 86-94.
14. Clark D. and Chiodo L. A. (1988) Electrophysiological and pharmacological characterization of identified nigrostriatal and mesoaccumbens dopamine neurons in the rat. Synapse 2, 474-485.
15. Delgado J. M. R., DeFeudis F. V., Roth R. H., Ryugo D. K., and Mitruka B. M. (1972) Dialytrode for long term intracerebral perfusion in awake monkeys. Arch. Int. Pharmacodyn. 198, 9-21.
16. Devinsky O., Emoto S., Nadi N. S., and Theodore W. H. (1993) Cerebrospinal fluid levels of neuropeptides, cortisol, and amino acids in patients with epilepsy. Epilepsia 34, 255-261.
17. Emmers R. and Akert K. (1963) A Stereotaxic Atlas of the Brain of the Squirrel Monkey (Saimiri sciureus). University of Wisconsin Press, Madison, Wisconsin.
18. 3H-monoamines from field-stimulated rat brain slices. Acta Physiol. Scand. Suppl. 371, 35-44.
19. Hassler R. (1937) Zur Normalanatomic der Substantia nigra. Versuch einer architektonischen Gliederung. J. Psych. Neurol. 48, 1-55.
20. Hornykiewicz O. and Kish S. J. (1986) Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45, 19-34.
21. Huntley G. W., Morrison J. H., Prikhozhan A., and Sealfon S. C. (1992) Localization of multiple dopamine receptor subtype mRNAs in human and monkey motor cortex and striatum. Mol. Brain Res. 15, 181-188.
22. Ichikawa S., Sasaoka T., and Nagatsu T. (1991) Primary structure of mouse tyrosine hydroxylase deduced from its cDNA. Biochem. Biophys. Res. Commun. 176, 1610-1616.
23. Imperato A., Tanda G., Frau R., and Di Chiara G. (1988) Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats. J. Pharmacol. Exp. Ther. 245, 257-267.
24. Iyer R. N., Nobiletti J. B., Jatlow P. I., and Bradbury C. W. (1995) Cocaine and cocaethylene: effects on extracellular dopamine in the primate. Psychopharmacology (Berl.) 120, 150-155.
25. Kanthan R., Shuaib A., Griebel R., and Miyashita H. (1995) Intracerebral human microdialysis in vivo study of an acute focal ischemic model of the human brain. Stroke 26, 870-873.
26. Kehr W. A., Carlsson M., Lidqvist T. M., and Atack C. (1972) Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activity. J. Pharm. Pharmacol. 24, 744-754.
27. 3H]raclopride. Neurosci. Lett. 66, 85-90
28. Kolachana B. S., Saunders R. C., and Weinberger D. R. (1994) An improved methodology for routine in vivo microdialysis in nonhuman primates. J. Neurosci. Methods 55, 1-6.
29. Kurata K. and Shibata R. (1990) Biphasic effect of locally applied apomorphine and 2,3,4,5-tetrahydro-7,8-dihydoxy-1-phenyl-1H-3-benzazepine on the release of striatal dopamine investigated by means of brain dialysis. Neurosci. Lett 117, 264-268.
30. Kurata K. and Shibata R. (1991) Differential effect of haloperidol on dopamine release and metabolism in caudate putamen and anteromedial frontal cortex using intracerebral dialysis. Pharmacology 42, 1-9.
31. Lacey M. G., Mercuri N. B., and North R. A. (1987) Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta. J. Physiol. (Lond.) 392, 397-416.
32. Lavoie B., Smith Y., and Parent A. (1989) Dopaminergic innervation of the basal ganglia in the squirrel monkey as revealed by tyrosine hydroxylase immunohistochemistry. J. Comp. Neurol. 289, 36-52.
33. Lewis D. A., Melchitzky D. S., and Haycock J. W. (1994) Expression and distribution of two isoforms of tyrosine hydroxylase in macaque monkey brain. Brain Res. 656, 1-13.
34. Losonczy M. F., Davidson M., Davis K. L., and Meltzer H. Y. (1987) The dopamine hypothesis of schizophrenia, in Psychopharmacology: The Third Generation of Progress (Meltzer, H. Y., ed), pp. 715-726. Raven Press, New York.
35. 2 dopamine receptors in caudate-putamen of nonhuman primates (Macaca fascicularis). J. Neurochem. 51, 934-943.
36. Magarinos-Ascone C., Buno W., and Garcia-Austt E. (1992) Activity in monkey substantia-nigra neurons related to a simple learned movement. Exp. Brain Res. 88, 283-291.
37. Martin G. E., Williams M., Pettibone D. J., Yarbough G. G., Clineschmidt B. V., and Jones J. H. (1984) Pharmacologic profile of a novel potent direct-acting dopamine agonist, (+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO]. J. Pharmacol. Exp. Ther. 230, 569-576.
38. Matsubayashi H., Amano T., Hongjing Y., Kohno Y., and Sasa M. (1995) Action of intravenously administered talipexole on the rat striatal neurons receiving excitatory input from nigral dopamine neurons. Psychopharmacology (Berl.) 120, 369-375.
39. Meador-Woodruff J. H., Damask S. P., and Watson S. J. (1994) Differential expression of autoreceptors in the descending dopamine systems of the human brain. Proc. Natl. Acad. Sci. USA 91, 8297-8301.
40. Meltzer L. T., Christoffersen C. L., Corbin A. E., Ninteman F. W., Serpa K. A., Wiley J. N., Wise L. D., and Heffner T. G. (1995) CI-1007, a dopamine partial agonist and potential antipsychotic agent II. Neurophysiological and behavioral effects. J. Pharmacol. Exp. Ther. 274, 912-920.
41. Meyerson B. A., Linderoth B., Karlsson H., and Ungerstedt U. (1990) Microdialysis in the human brain: extracellular measurements in the thalamus of parkinsonian patients. Life Sci. 46, 301-308.
42. Moghaddam B., Berridge C. W., Goldman-Rakic P. S., Bunney B. S., and Roth R. H. (1993) In vivo assessment of basal and drug-induced dopamine release in cortical and subcortical regions of the anesthetized primate. Synapse 13, 215-222.
43. O'Malley K. L., Anhalt M. J., Martin B. M., Kelsoe J. R., Winfield S. L., and Ginns E. I. (1987) Isolation and characterization of the human tyrosine hydroxylase gene: identification of 5′ alternative splice sites responsible for multiple mRNAs. Biochemistry 26, 6910-6914.
44. Parent A. and Hazrati L. N. (1994) Multiple striatal representation in primate substantia nigra. J. Comp. Neurol. 344, 305-320.
45. Parent A., Cote P. Y., and Lavoie B. (1995) Chemical anatomy of primate basal ganglia. Prog. Neurobiol. 46, 131-197.
46. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, Orlando, Florida.
47. Persson L. and Hillered L. (1992) Chemical monitoring of neurosurgical intensive care patients using intracerebral microdialysis. J. Neurosurg. 76, 72-80.
48. Pifl C., Pichler L., Kobinger W., and Hornykiewicz O. (1988) The dopamine autoreceptor agonist, B-HT 920, preferentially reduces brain dopamine release in vivo: biochemical indices of brain dopamine, noradrenaline and serotonin in ventriculocisternal perfusates in the cat. Eur. J. Pharmacol. 153, 33-44.
49. Puglisi-Allegra S. and Cabib S. (1988) The D2 dopamine receptor agonist LY 171555 induces catalepsy in the mouse. Pharmacol. Biochem. Behav. 30, 765-768.
50. Pugsley T. A., Davis M. D., Akunne H. C., Cooke L. W., Whetzel S. Z., MacKenzie R. G., Shih Y. H., Van Leeuwen D. H., De-Mattos S. B., Georgic L. M., Caprathe B. W., Wright J. C., Jaen J. C., Wise L. D., and Heffner T. G. (1995a) CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects. J. Pharmacol. Exp. Ther. 274, 898-911.
51. Pugsley T. A., Davis M. D., Akunne H. C., MacKenzie R. G., Shih Y. H., Damsma G., Wikstrom H., Whetzel S. Z., Georgic L. M., Cooke L. W., DeMattos S. B., Corbin A. E., Glase S. A., Wise L. D., Dijkstra D., and Heffner T. G. (1995b) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J. Pharmacol. Exp. Ther. 275, 1355-1366.
52. Rappaport M. S., Sealfon S. C., Prikhozhan A., Huntley G. W., and Morrison J. H. (1993) Heterogeneous distribution of D1, D2. and D5 receptor mRNAs in monkey striatum. Brain Res. 616, 242-250.
53. Roberts A. C., De Salvia M. A., Wilkinson L. S., Collins P., Muir J. L., Everitt B. J., and Robbins T. W. (1994) 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhanced performance on an analog of the Wisconsin card sort test: possible interactions with subcortical dopamine. J. Neurosci. 14, 2531-2544.
54. Robinson T. E. and Camp D. M. (1991) The feasibility of repeated microdialysis for within-subjects design experiments: studies on the mesostriatal dopamine system, in Microdialysis in the Neurosciences (Robinson T. E. and Justice J. B., eds), pp. 189-234. Elsevier Science Publishers, New York.
55. + (1-methyl-4-phenylpyridinium) in three species: microdialysis of dopamine and metabolites in mouse, rat, and monkey striatum. Neurosci. Lett. 106, 275-281.
56. Ronne-Engstrom E., Hillered L., Flink R., Spannare B., Ungerstedt U., and Carlson H. (1992) Intracerebral microdialysis of extracellular amino acids in the human epileptic focus. J. Cereb. Blood Flow Metab. 12, 873-876.
57. Rosenzweig-Lipson S. and Barrett J. E. (1995) K-channel blockers attenuate the presynaptic effects of the D2/D3 agonist quinpirole in monkeys. Pharmacol. Biochem. Behav. 51, 843-848.
58. Rosenzweig-Lipson S. and Bergman J. (1993) Modification of the behavioral effects of the selective dopamine D2 agonist (+)-PHNO by dopamine antagonists in monkeys. J. Pharmacol. Exp. Ther. 265, 1039-1046.
59. Roth R. H. (1984) CNS dopamine autoreceptors: distribution, pharmacology and function. Ann. NY Acad. Sci. 430, 27-53.
60. Santiago M. and Westerink B. H. C. (1990) Characterization of the in vivo release of dopamine as recorded by different types of intracerebral microdialysis probes. Naunyn Schmiedebergs Arch. Pharmacol. 342, 407-414.
61. Santiago M. and Westerink B. H. C. (1991) The regulation of dopamine release from nigrostriatal neurons in conscious rats: the role of somatodendritic autoreceptors. Eur. J. Pharmacol. 204, 79-85.
62. Saunders R. C., Kolachana B. S., and Weinberger D. R. (1994) Local pharmacological manipulation of extracellular dopamine levels in the dorsolateral prefrontal cortex and caudate nucleus in the rhesus monkey: an in vivo microdialysis study. Exp. Brain Res. 98, 44-52.
63. Seeman P. (1987) The absolute density of neurotransmitter receptors in brain: example for dopamine receptors. J. Pharmacol. Methods 17, 347-360.
64. Seeman P., Bzowej N. H., Guan H. C., Bergeron C., Becker L. E., Reynolds G. P., Bird E. D., Riederer P., Jellinger K., Watanabe S., and Tourtellotte W. W. (1987) Human brain dopamine receptors in children and ageing adults. Synapse 1, 399-404.
65. Skirboll S., Wang J., Mefford I., Hsiao J., and Bankiewicz K. S. (1990) In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. Exp. Neurol. 110, 187-193.
66. Timmerman W. and Westerink B. H. C. (1991) Importance of the calcium content infused during microdialysis for the effects induced by D2 agonists on the release of dopamine in the striaturn of the rat. Neurosci. Lett. 131, 93-96.
67. Timmerman W., Westerink B. H. C., De Vries J., Tepper P. G., and Horn A. S. (1989) Microdialysis and striatal dopamine release: stereoselective actions of the enantiomers of N-0437. Eur. J. Pharmacol. 162, 143-150.
68. van Domburg P. H. M. F. and ten Donkelaar H. J. (1991) Advances in Anatomy Embryology and Cell Biology, Vol. 121: The Human Substantia Nigra and Ventral Tegmental Area. A Neuroanatomical Study with Notes on Aging and Aging Diseases. Springer-Verlag, New York.
69. Wiedemann K., Krieg J. C., Loycke A., and Holsboer F. (1992) Novel dopamine autoreceptor agonists B-HT 920 and EMD 49980 in the treatment of patients with schizophrenia, in Novel Antipsychotic Drugs (Meltzer H. Y., ed.), pp. 91-98. Raven Press, New York.